An ongoing theme is to grow the North American business by expanding sales of key pharmaceuticals marketed in North America, including Latuda, Orgovyx and Gemtesa. This also includes offsetting revenue declines following the end of exclusive marketing periods through growth in other key products and sales milestone income, thereby increasing revenue and profit.